Nanoform begins first-in-human trial by year end

By The Science Advisory Board staff writers

October 20, 2020 -- Nanoform Finland plans to start the first human clinical trial of its drug candidate using the company's Controlled Expansion of Supercritical Solutions (CESS) technology by the end of 2020. The clinical trial is a progression of Nanoform's first good manufacturing practice (GMP) campaign in partnership with Quotient Sciences.

The clinical trial will investigate the behavior of an immediate-release nanoformed formulation of piroxicam and an anti-inflammatory drug. Nanoform will manufacture the nanoformed active pharmaceutical ingredient, which will then be transferred to Quotient's facilities in Nottingham, U.K. Quotient will develop a standard drug formulation and administer it to healthy volunteers.

Nanoform's in vivo and in vitro results demonstrate that reduction in drug particle size with Nanoform's CESS nanoforming technology can improve the pharmacokinetic properties of drugs.

The company is on track to achieve all its near-term business targets for 2020 and 2021 announced in relation to the initial public offering (IPO).

If you like this content, please share it with a colleague!